Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy

Registration Number
NCT06393309
Lead Sponsor
Mazandaran University of Medical Sciences
Brief Summary

This study aimed to compare the long-term efficacy and safety of levetiracetam and valproate in treatment of idiopathic generalized epilepsy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
169
Inclusion Criteria
  • Diagnosis of juvenile myoclonic epilepsy or generalized tonic-clonic seizure alone
  • Regular monotherapy with levetiracetam or sodium valproate
Read More
Exclusion Criteria
  • Poor drug adherence
  • Pregnancy
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
LevetiracetamLevetiracetamPatients with idiopathic generalized epilepsy who were under treatment with levetiracetam
Sodium valproateSodium valproatePatients with idiopathic generalized epilepsy who were under treatment with valproate
Primary Outcome Measures
NameTimeMethod
Seizure free rate1 to 5 years

The percent of patients who remained seizure free on treatment

Time to first seizure1 to 5 years

The interval between start of treatment and recurrence of seizure

Secondary Outcome Measures
NameTimeMethod
Retention rate1 to 5 years

The percent of patients who remained on treatment with levetiracetam or valproate

Time to withdrawal1 to 5 years

The interval between start and withdrawal of treatment

Trial Locations

Locations (1)

Bu Ali Sina Hospital

🇮🇷

Sari, Mazandaran, Iran, Islamic Republic of

© Copyright 2024. All Rights Reserved by MedPath